Axsome Q4 revenue $196M (+65% YoY); AXS-05 PDUFA set for April 30, 2026

Axsome Therapeutics, Inc.

2025-FY EPS reported -$3.68 revenue$638,496,000

Total net product revenue Q4 $196.0M, FY $638.5M (+66% YoY); AUVELITY sales $507.1M (+74%).
Net loss Q4 $28.6M ($0.56/share), FY $183.2M ($3.68); cash $322.9M; operating loss narrowed.
sNDA for AXS-05 (Alzheimer's agitation) granted Priority Review, PDUFA target April 30, 2026.
SUNOSI generic patent litigation with Alkem settled; license delays generic entry until 2040.
Acquired AXS-17 (GABA A PAM) for epilepsy; NDA submission for AXS-12 narcolepsy expected Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.